Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332317 | 0.87 | ESR1 (0.51) | TRPV4ARESR1ESR2EGLN2 | |
| SCHEMBL18639801 | 0.84 | TRPV4 (0.43) | TRPV4ARESR1ESR2TAAR1 | |
| SCHEMBL24167421 | 0.84 | TRPV4 (0.43) | TRPV4ARESR1ESR2TAAR1 | |
| SCHEMBL16177628 | 0.84 | TRPV4 (0.43) | TRPV4ARESR1ESR2TAAR1 | |
| SCHEMBL83482 | 0.82 | ESR1 (0.44) | TRPV4ARESR1ESR2EGLN2 | |
| SCHEMBL83963 | 0.81 | NQO1 (0.50) | TRPV4ARESR1ESR2EGLN2 | |
| SCHEMBL25564462 | 0.80 | CYP3A4 (0.45) | TRPV4ARESR1ESR2EGFR | |
| SCHEMBL8063680 | 0.78 | ESR1 (0.53) | TRPV4ARESR1ESR2CA12 | |
| SCHEMBL185766 | 0.78 | TRPV4 (0.64) | TRPV4ESR1ESR2CA12CA9 | |
| SCHEMBL6649045 | 0.76 | TRPV4 (0.61) | TRPV4MEN1KMT2AEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702085-A | Method for regulating specific surface area of carbon material | 三明学院 | 2024-09-27 | — | — | CN | claimed |
| CN-114984928-A | Modified porous cyclodextrin polymer material and preparation method and application thereof | 中南大学 | 2022-09-02 | — | — | CN | claimed |
| CN-110283173-B | Perylene bisimide compound and preparation method and application thereof | 济南大学 | 2021-11-16 | — | — | CN | claimed |
| CN-110283173-A | A kind of imide analog compounds and its preparation method and application | 济南大学 | 2019-09-27 | — | — | CN | claimed |
| JP-4300861-A | — | — | None | — | — | JP | disclosed |
| JP-4279560-A | — | — | None | — | — | JP | disclosed |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12421193-B2 | GPR52 modulators and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-120081885-A | Substituted phenyl glycoside compound and preparation method and application thereof | 浙江大学 | 2025-06-03 | — | — | CN | disclosed |
| EP-0571652-A1 | Liquid crystalline substituted dihydrobenzene derivatives | L.C.C. CONSULTANTS CO., LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| JP-H04300861-A | TRANS-ETHYLENE DERIVATIVE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELECTROOPTICAL ELEMENT | SEIMI CHEM KK | 1992-10-23 | — | — | JP | disclosed |
| US-5156763-A | Liquid crystals | THE SECRETARY OF STATE FOR FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-20 | — | — | US | disclosed |
| JP-H04279560-A | DIFLUOROCYANO COMPOUND, LIQUID CRYSTAL COMPOSITION AND ELECTROOPTICAL ELEMENT OF LIQUID CRYSTAL | SEIMI CHEM KK | 1992-10-05 | — | — | JP | disclosed |
| US-5069814-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1991-12-03 | — | — | US | disclosed |
| EP-0407438-A1 | LATERALLY FLUORINATED 4-CYANOPHENYL AND 4'-CYANOBIPHENYL BENZOATES. | SECR DEFENCE BRIT (GB) | 1991-01-16 | — | — | EP | disclosed |
| WO-1989008102-A1 | LATERALLY FLUORINATED 4-CYANOPHENYL AND 4'-CYANOBIPHENYL BENZOATES | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNI (GB) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | TRPV4 1462/4885AR 465/4885ESR1 400/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885AR 336/4885ESR1 2800/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | TRPV4 4393/4885AR 572/4885ESR1 2356/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 909/4885AR 1495/4885ESR1 3515/4885 |
| US-12421193-B2 | GPR52 modulators and methods of use | GPR52, GPR68, GPR35 | TRPV4 488/4885AR 743/4885ESR1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.